Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials

BACKGROUND: Two randomised, placebo-controlled trials—BENCHMRK-1 and BENCHMRK-2—investigated the efficacy and safety of raltegravir, an HIV-1 integrase strand-transfer inhibitor. We report final results of BENCHMRK-1 and BENCHMRK-2 combined at 3 years (the end of the double-blind phase) and 5 years...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Lancet Infect Dis
Glavni autori: Eron, Joseph J, Cooper, David A, Steigbigel, Roy T, Clotet, Bonaventura, Gatell, Jose M, Kumar, Princy N, Rockstroh, Jurgen K, Schechter, Mauro, Markowitz, Martin, Yeni, Patrick, Loutfy, Mona R, Lazzarin, Adriano, Lennox, Jeffrey L, Strohmaier, Kim M, Wan, Hong, Barnard, Richard J O, Nguyen, Bach-Yen T, Teppler, Hedy
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6083850/
https://ncbi.nlm.nih.gov/pubmed/23664333
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1473-3099(13)70093-8
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items